{"nctId":"NCT01165177","briefTitle":"Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older","startDateStruct":{"date":"2010-08-02","type":"ACTUAL"},"conditions":["Herpes Zoster"],"count":16165,"armGroups":[{"label":"GSK1437173A group","type":"EXPERIMENTAL","interventionNames":["Biological: Herpes Zoster Vaccine GSK1437173A"]},{"label":"Placebo group","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Herpes Zoster Vaccine GSK1437173A","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes will comply with the requirements of the protocol;\n* Written informed consent obtained from the subject;\n* A male or female aged 50 years or older at the time of the first vaccination;\n* Female subjects of non-childbearing potential may be enrolled in the study;\n\nFor this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.\n\nOR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 days prior to vaccination, and has a negative urine pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series;\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period;\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product;\n* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy;\n* History of HZ;\n* Previous vaccination against varicella or HZ;\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation;\n* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study;\n* Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period;\n* Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine;\n* Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study;\n* Acute disease and/or fever at the time of enrollment;\n* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Pregnant or lactating female;\n* Female planning to become pregnant or planning to discontinue contraceptive precautions.","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Confirmed Herpes Zoster (HZ) Cases","description":"Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"87","spread":null},{"groupId":"OG005","value":"75","spread":null},{"groupId":"OG006","value":"48","spread":null},{"groupId":"OG007","value":"210","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)","description":"The incidence of PHN was calculated using the modified total vaccinated chort.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"8","spread":null},{"groupId":"OG007","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain","description":"Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"91","spread":null},{"groupId":"OG005","value":"74","spread":null},{"groupId":"OG006","value":"56","spread":null},{"groupId":"OG007","value":"221","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Confirmed HZ Episode Related Mortality","description":"The analysis focused on the number of subjects who died due to HZ","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With HZ Related Complications","description":"The analysis focused on the incidence of HZ complications in subjects with confirmed HZ","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Confirmed HZ Episode Related Hospitalizations","description":"The analysis focused on confirmed HZ episode related hospitalizations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ","description":"The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"82","spread":null},{"groupId":"OG005","value":"63","spread":null},{"groupId":"OG006","value":"45","spread":null},{"groupId":"OG007","value":"190","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ","description":"The analysis focused on subjects taking pain medication due to HZ","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"82","spread":null},{"groupId":"OG005","value":"63","spread":null},{"groupId":"OG006","value":"45","spread":null},{"groupId":"OG007","value":"190","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days With Severe 'Worst' HZ-associated Pain.","description":"Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":"11.8"},{"groupId":"OG001","value":"78.0","spread":"0.0"},{"groupId":"OG002","value":"9.0","spread":"4.2"},{"groupId":"OG003","value":"20.6","spread":"26.8"},{"groupId":"OG004","value":"28.7","spread":"48.4"},{"groupId":"OG005","value":"21.6","spread":"29.3"},{"groupId":"OG006","value":"44.0","spread":"74.4"},{"groupId":"OG007","value":"30.2","spread":"51.9"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations","description":"The analysis focused on confirmed HZ episode related hospitalizations and deaths.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With HZ Related Complications, by Complication Type","description":"Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Pain Medication Associated With HZ","description":"The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed on participants with confirmed HZ.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"82","spread":null},{"groupId":"OG005","value":"63","spread":null},{"groupId":"OG006","value":"45","spread":null},{"groupId":"OG007","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"30","spread":null},{"groupId":"OG005","value":"23","spread":null},{"groupId":"OG006","value":"14","spread":null},{"groupId":"OG007","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"26","spread":null},{"groupId":"OG005","value":"19","spread":null},{"groupId":"OG006","value":"9","spread":null},{"groupId":"OG007","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"26","spread":null},{"groupId":"OG005","value":"21","spread":null},{"groupId":"OG006","value":"22","spread":null},{"groupId":"OG007","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Pain Medication Associated With HZ","description":"The analysis was performed on subjects with a confirmed HZ episode","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"14.5"},{"groupId":"OG001","value":"20.5","spread":"16.3"},{"groupId":"OG002","value":"63.0","spread":"0.0"},{"groupId":"OG003","value":"26.0","spread":"21.6"},{"groupId":"OG004","value":"49.2","spread":"121.5"},{"groupId":"OG005","value":"74.3","spread":"166.3"},{"groupId":"OG006","value":"127.7","spread":"266.9"},{"groupId":"OG007","value":"76.1","spread":"181.5"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3120","spread":null},{"groupId":"OG001","value":"352","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1225","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"810","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2807","spread":null},{"groupId":"OG001","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1151","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"762","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3463","spread":null},{"groupId":"OG001","value":"490","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"293","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1665","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1153","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, GI (gastrointestinal) symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), fever \\[defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = temperature\\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1395","spread":null},{"groupId":"OG001","value":"531","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1153","spread":null},{"groupId":"OG001","value":"355","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"465","spread":null},{"groupId":"OG001","value":"263","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"317","spread":null},{"groupId":"OG001","value":"141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1112","spread":null},{"groupId":"OG001","value":"511","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"891","spread":null},{"groupId":"OG001","value":"341","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1446","spread":null},{"groupId":"OG001","value":"377","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1231","spread":null},{"groupId":"OG001","value":"265","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"632","spread":null},{"groupId":"OG001","value":"166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"539","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"500","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"420","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1456","spread":null},{"groupId":"OG001","value":"379","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1270","spread":null},{"groupId":"OG001","value":"279","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"495","spread":null},{"groupId":"OG001","value":"183","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1249","spread":null},{"groupId":"OG001","value":"340","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1107","spread":null},{"groupId":"OG001","value":"219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1474","spread":null},{"groupId":"OG001","value":"274","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1314","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"947","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"838","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"645","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"571","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2006","spread":null},{"groupId":"OG001","value":"728","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1724","spread":null},{"groupId":"OG001","value":"522","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"787","spread":null},{"groupId":"OG001","value":"386","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"591","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1714","spread":null},{"groupId":"OG001","value":"700","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1470","spread":null},{"groupId":"OG001","value":"469","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2023","spread":null},{"groupId":"OG001","value":"529","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"236","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1791","spread":null},{"groupId":"OG001","value":"390","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1232","spread":null},{"groupId":"OG001","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1082","spread":null},{"groupId":"OG001","value":"177","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"940","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"813","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)","description":"Number of subjects with any and grade 3 solicited and unsolicited symptoms were tabulated","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3766","spread":null},{"groupId":"OG001","value":"1691","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"759","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)","description":"Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With AEs With Any and Related Medically Attended Visit","description":"Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2952","spread":null},{"groupId":"OG001","value":"3072","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs)","description":"Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3534","spread":null},{"groupId":"OG001","value":"2426","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"609","spread":null},{"groupId":"OG001","value":"298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2199","spread":null},{"groupId":"OG001","value":"439","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"594","spread":null},{"groupId":"OG001","value":"590","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"727","spread":null},{"groupId":"OG001","value":"731","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine","description":"The number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine were tabulated","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Fatal SAEs","description":"Number of subjects with fatal SAEs during the entire study period were tabulated","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":null},{"groupId":"OG001","value":"221","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":727,"n":7695},"commonTop":["Pain","Headache","Fatigue","Myalgia","Erythema"]}}}